- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Aurobindo Pharma Ltd. (ARBN)
Aurobindo Pharma Ltd. stock price live, this page displays NSE ARBN stock exchange data. View the ARBN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Aurobindo Pharma Ltd. real time stock price chart below.
What Is the Aurobindo Pharma Ltd. Stock Price Today?
The Aurobindo Pharma Ltd. stock price today is 1,150.20.
What Is the Stock Symbol for Aurobindo Pharma Ltd.?
The stock symbol for Aurobindo Pharma Ltd. is "ARBN."
What Stock Exchange Does Aurobindo Pharma Ltd. Trade On?
Aurobindo Pharma Ltd. is listed and trades on the NSE stock exchange.
Is Aurobindo Pharma Ltd. a Good Stock to Buy?
Determining whether Aurobindo Pharma Ltd.—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ARBN quote. (ISIN: INE406A01037)
What Is the Aurobindo Pharma Ltd. Stock Price Today?
The Aurobindo Pharma Ltd. stock price today is 1,150.20.
What Is the Stock Symbol for Aurobindo Pharma Ltd.?
The stock symbol for Aurobindo Pharma Ltd. is "ARBN."
What Stock Exchange Does Aurobindo Pharma Ltd. Trade On?
Aurobindo Pharma Ltd. is listed and trades on the NSE stock exchange.
Is Aurobindo Pharma Ltd. a Good Stock to Buy?
Determining whether Aurobindo Pharma Ltd.—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ARBN quote. (ISIN: INE406A01037)
1,150.20
-5.00(-0.43%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1,135.60
1,155.00
52 wk Range
1,010.00
1,592.00
ARBN Scorecard
Full Analysis
Management has been aggressively buying back shares
ARBN is not included in our AI-picked strategies. See which stocks are.
Review Strategies
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1,135.601,155.00
52 wk Range
1,010.001,592.00
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
ARBN Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
1,410.50
Upside
+22.63%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a low earnings multiple
- Aurobindo Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Aurobindo Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Aurobindo Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Aurobindo Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Aurobindo Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Aurobindo Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Aurobindo Pharma Ltd. Company Profile
Aurobindo Pharma Limited, a biopharmaceutical company, engages in the manufacture of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, Puerto Rico, and internationally. The company offers formulation in form of oral solids, liquids, injectables, and vaccines, as well as over-the-counter drugs; and active pharmaceutical ingredients (APIs), biosimilars, biocatalysts, peptides, and hormones targeting key therapeutic areas, including central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and provides project-based chemistry contract services that cover the clinical stage through to manufacturing and management of the entire drug lifecycle in the API space for sterile and non-sterile penicillin’s, cephalosporins, penems, and non-beta lactams. The company was incorporated in 1986 and is headquartered in Hyderabad, India.
Compare ARBN to Peers and Sector
Metrics to compare | ARBN | Peers Peers - average of corresponding metrics from companies closely matching ARBN: MOREPENLAB, DRREDDY, APLLTD, TORNTPHARM, IPCALAB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipARBNPeersSector |
|---|---|---|---|---|
P/E Ratio | 19.2x | 32.1x | −0.5x | |
PEG Ratio | 1.83 | 1.13 | 0.00 | |
Price/Book | 2.0x | 3.9x | 2.6x | |
Price / LTM Sales | 2.1x | 3.7x | 3.1x | |
Upside (Analyst Target) | 21.7% | 7.9% | 50.4% | |
Fair Value Upside | Unlock | −1.3% | 8.7% | Unlock |
Analyst Ratings
23 Buy
1 Hold
4 Sell
Ratings:
28 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 1,410.50
(+22.63% Upside)
Earnings
Latest Release
May 26, 2025
EPS / Forecast
15.56 / 17.53
Revenue / Forecast
83.82B / 80.85B
FAQ
What Is the Aurobindo Pharma (ARBN) Stock Price Today?
The Aurobindo Pharma stock price today is 1,150.20
What Stock Exchange Does Aurobindo Pharma Trade On?
Aurobindo Pharma is listed and trades on the India National Stock Exchange stock exchange.
What Is the Stock Symbol for Aurobindo Pharma?
The stock symbol for Aurobindo Pharma is "ARBN."
What Is the Aurobindo Pharma Market Cap?
As of today, Aurobindo Pharma market cap is 668.04B.
What Is Aurobindo Pharma's Earnings Per Share (TTM)?
The Aurobindo Pharma EPS (TTM) is 59.81.
When Is the Next Aurobindo Pharma Earnings Date?
Aurobindo Pharma will release its next earnings report on 06 Aug 2025.
From a Technical Analysis Perspective, Is ARBN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Aurobindo Pharma Stock Split?
Aurobindo Pharma has split 3 times.
How Many Employees Does Aurobindo Pharma Have?
Aurobindo Pharma has 26015 employees.
What is the current trading status of Aurobindo Pharma (ARBN)?
As of 14 Jun 2025, Aurobindo Pharma (ARBN) is trading at a price of 1,150.20, with a previous close of 1,155.20. The stock has fluctuated within a day range of 1,135.60 to 1,155.00, while its 52-week range spans from 1,010.00 to 1,592.00.
What Is Aurobindo Pharma (ARBN) Price Target According to Analysts?
The average 12-month price target for Aurobindo Pharma is INR1410.5, with a high estimate of INR1930 and a low estimate of INR1100. 23 analysts recommend buying the stock, while 4 suggest selling, leading to an overall rating of Buy. The stock has an +22.63% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.